Zhaoke Ophthalmology-B (06622) announced its 2025 annual results, with revenue of 31.974 million yuan, a decrease of 53.88% year-on-year. The net loss after tax was approximately 209 million yuan, narrowing by 12% compared to the previous year. According to the announcement, the reduction in loss was primarily due to the Group's continued strict control over administrative expenses and sales and distribution costs, reflecting enhanced cost control and improved operational structure efficiency during the year. Additionally, research and development expenses decreased as several key development milestones were achieved, and the absence of non-recurring expenses incurred in the prior year further contributed to the improvement. Although there was no one-time licensing revenue recognized as in the previous year, and lower interest rates in 2025 led to a reduction in bank interest income, the Group still achieved a substantial narrowing of its annual loss.